Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo’s New Papa: CEO Brings Product Development Know-How To Post

This article was originally published in The Tan Sheet

Executive Summary

Joseph Papa brings 30 years of experience in healthcare and specialty generic pharmaceutical industries to his new position as president and CEO of Perrigo, the private-label manufacturer announced Sept. 11

You may also be interested in...



Perrigo Makes Softgel Move As Mylan Continues Takeover Play

Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.

Perrigo Makes Softgel Move As Mylan Continues Takeover Play

Acquiring Patheon’s Mexico plant not only adds softgel capabilities to Perrigo’s operations but also boosts its value as an acquisition target. The firm continues integrating Omega Pharma’s operations and managing its OTC private label and other businesses as Mylan presses for Perrigo shareholders to consider its bid.

Perrigo Builds Sales On Smoking Cessation, Eyes Prilosec OTC In 2007

Pursuit of private-label omeprazole for a possible 2007 launch fits Perrigo's ongoing strategy of focusing on new products to drive sales growth

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel